Glenn Hanna
Director, Center for Salivary and Rare Head and Neck Cancers · Mass General Brigham
Credentials: · · · ·
History
- Present
Center for Salivary and Rare Head and Neck Cancers · Mass General Brigham
- 2014–2016
Medical Oncology
- 2011–2014
Internal Medicine
Research
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Cancer Discovery · 2018 · 495 citations
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
Nature Genetics · 2018 · 472 citations
Clinical Cancer Research · 2020 · 335 citations
49 papers
35 papers
30 papers
29 papers
28 papers
27 papers
- NC
22 papers
19 papers
Clinical trials
- 2030–2034
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
Principal investigator · Withdrawn · Phase 2
Actuate Therapeutics Inc.
- 2026–2030
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Principal investigator · Recruiting · Phase 2
Dana-Farber Cancer Institute
- 2025–2027
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Principal investigator · Recruiting · Phase 2
Glenn J. Hanna
- 2025–2029
Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease
Principal investigator · Recruiting · Phase 2
Glenn J. Hanna